GT Biopharma, Inc. (GTBP) is a clinical-stage biopharmaceutical company emphasizing on developing novel therapeutics for the treatment of cancer and other inflammatory diseases. The company was initially incorporated in Delaware in 1965 and reincorporated in Nevada in 2013. As of today, GT Biopharma operates under the stewardship of Anthony J. Cataldo, who serves as the company’s Chairman and Chief Executive Officer.
GT Biopharma is heavily invested in developing its proprietary TriKE™ technology, which is designed to harness and enhance the cancer killing abilities of a patient's immune system NK cells. TriKE™ technology is essentially a platform that generates targeted NK cell engagers binding cancer cells and NK cells. NK cells, otherwise known as natural killer cells, are the immune system's primary line of defense against cancer and various infectious diseases.
Among the most notable medications in GT Biopharma's pipeline is GTB-3550, a drug based on the company's TriKE™ technology that's being developed for the treatment of various hematologic malignancies like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and others. GTB-3550 is currently under Phase I/II clinical trial, demonstrating promising results by showing a reduction in AML blast levels with no adverse reactions.
Furthermore, the company has laid out its research and development focus on developing therapies for B-cell lymphoma (GTB-4550), prostate cancer (GTB-5550), triple negative breast cancer (GTB-6550), and lung cancer (GTB-7550), all utilizing the proprietary TriKE™ technology.
In its mission to expand their portfolio and to break new grounds in the pharmaceutical industry, GT Biopharma is committed to develop and commercialize first-in-class, targeted immunotherapies to treat cancer. The company is dedicated to improving patient health and increasing longevity by utilizing its proprietary NK-engager platform technology to create potent, targeted therapies.
Despite its noted advancements, like any other research-based pharmaceutical company, GT Biopharma faces its share of challenges. The pharmaceutical industry consists of long development cycles, requiring a significant amount of capital and research to ensure the safety and efficacy of its products.
Nevertheless, with a passionate team of experienced scientists and committed management, GT Biopharma, Inc. is steadily pushing forward, striving to create a new frontier in targeted cancer treatments. As the company works toward its goal, the future looks promising for those waiting on the revolutionary cancer treatments the company has in its pipeline.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
GT Biopharma recently increased its Series M Preferred Stock private placement, adding a new investor and expanding the offering size. The company filed a First Amendment to its Securities Purchase Agreement, raising the total purchase price to $7.75 million and increasing authorized shares. This move also includes registration rights for the public resale of common stock.
GT Biopharma, Inc. (NASDAQ: GTBP) announced it would host a live presentation to discuss the development of its TriKE® platform for cancer treatment, featuring CEO Michael Breen and Dr. Jeffrey Miller. The presentation will cover clinical progress in blood cancers and solid tumors, insights from dose escalation, competitive positioning, and future milestones. Following the announcement, GTBP shares surged by 19.2% to $7.37.
GT Biopharma (NASDAQ: GTBP) has advanced three TriKE candidates into clinical trials, leveraging its 2nd-generation platform for various cancers and autoimmune diseases. The company's unique TriKE design, incorporating nanobody technology and IL-15, aims for improved potency and patient-friendly subcutaneous dosing, particularly for solid tumors. With significant funding flowing into NK cell therapeutics, GT Biopharma is positioned among key players in the evolving immuno-oncology landscape, anticipating Phase 1 trial updates in late 2026.